Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:INVA NASDAQ:LXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.53+2.3%$8.87$6.00▼$10.32$2.42B0.574.98 million shs1.62 million shsCLDXCelldex Therapeutics$33.24+0.8%$31.99$19.52▼$35.79$2.61B0.95910,328 shs228,361 shsINVAInnoviva$23.74+0.8%$22.75$16.52▼$25.15$1.75B0.35752,776 shs126,906 shsLXRXLexicon Pharmaceuticals$2.22+2.5%$1.96$0.77▼$2.53$983.89M1.072.68 million shs1.21 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+1.86%+4.37%+12.30%-0.96%-6.05%CLDXCelldex Therapeutics-1.29%+2.04%+7.32%+4.10%+61.75%INVAInnoviva+3.97%+4.25%+4.94%+4.34%+13.21%LXRXLexicon Pharmaceuticals+0.47%+10.77%0.00%+28.57%+194.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.53+2.3%$8.87$6.00▼$10.32$2.42B0.574.98 million shs1.62 million shsCLDXCelldex Therapeutics$33.24+0.8%$31.99$19.52▼$35.79$2.61B0.95910,328 shs228,361 shsINVAInnoviva$23.74+0.8%$22.75$16.52▼$25.15$1.75B0.35752,776 shs126,906 shsLXRXLexicon Pharmaceuticals$2.22+2.5%$1.96$0.77▼$2.53$983.89M1.072.68 million shs1.21 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+1.86%+4.37%+12.30%-0.96%-6.05%CLDXCelldex Therapeutics-1.29%+2.04%+7.32%+4.10%+61.75%INVAInnoviva+3.97%+4.25%+4.94%+4.34%+13.21%LXRXLexicon Pharmaceuticals+0.47%+10.77%0.00%+28.57%+194.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70117.30% UpsideCLDXCelldex Therapeutics 2.82Moderate Buy$49.3048.31% UpsideINVAInnoviva 2.57Moderate Buy$36.2052.47% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55105.42% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, CLDX, BCRX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/22/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/18/2026LXRXLexicon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026CLDXCelldex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/10/2026CLDXCelldex Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $45.006/1/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/1/2026INVAInnoviva HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026INVAInnoviva BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.005/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.77$1.29 per share7.38($0.57) per share-16.71CLDXCelldex Therapeutics$865K3,016.45N/AN/A$7.93 per share4.19INVAInnoviva$420.69M4.17$5.26 per share4.51$15.71 per share1.51LXRXLexicon Pharmaceuticals$69.64M14.13N/AN/A$0.30 per share7.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A29.77N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)INVAInnoviva$271.17M$6.013.9510.06N/A119.89%33.33%22.67%8/5/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)Latest LXRX, CLDX, BCRX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026INVAInnoviva$0.43$0.44+$0.01$2.22$101.57 million$97.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92INVAInnoviva0.1921.1320.07LXRXLexicon Pharmaceuticals0.2418.8018.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AINVAInnoviva99.12%LXRXLexicon Pharmaceuticals74.70%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%INVAInnoviva2.01%LXRXLexicon Pharmaceuticals14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableINVAInnoviva10073.81 million72.33 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableLXRX, CLDX, BCRX, and INVA HeadlinesRecent News About These CompaniesHere's Why You Should Add LXRX Stock to Your Portfolio NowJune 22 at 11:41 AM | zacks.comIs Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comHow The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst UpdatesJune 4, 2026 | finance.yahoo.comLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsJune 3, 2026 | globenewswire.comLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comSA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRXMay 27, 2026 | msn.comLexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)May 26, 2026 | seekingalpha.comCiti Raises its Price Target on Lexicon Pharmaceuticals (LXRX)May 22, 2026 | insidermonkey.comLexicon Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:LXRXMay 21, 2026 | benzinga.comLexicon Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comLexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's ChangedMay 13, 2026 | finance.yahoo.comLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comLexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk MilestonesMay 9, 2026 | insidermonkey.comLexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target MaintainedMay 8, 2026 | tipranks.comLexicon Pharmaceuticals Secures New Hercules Term Loan FacilityMay 7, 2026 | theglobeandmail.comLexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comLexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1May 7, 2026 | zacks.comLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesMay 7, 2026 | globenewswire.comLexicon Pharmaceuticals Q1 2026 earnings previewMay 6, 2026 | msn.comLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalMay 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, CLDX, BCRX, and INVA Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$9.53 +0.22 (+2.32%) As of 12:06 PM Eastern This is a fair market value price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$33.24 +0.26 (+0.79%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Innoviva NASDAQ:INVA$23.74 +0.19 (+0.82%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Lexicon Pharmaceuticals NASDAQ:LXRX$2.22 +0.06 (+2.55%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Chevron’s Microsoft Deal Turns Natural Gas Into an AI Trade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
